Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. APGE
5. MU
6. GOOGL
7. DFTX
8. KR
9. MSTR
10. HOOD

Go back to Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

Mizuho Securities Reiterates Neutral Rating on Eli Lilly (LLY)

February 11, 2020 7:19 AM EST

Mizuho Securities analyst Vamil Divan reiterated a Neutral rating and $148.00 price target on Eli Lilly (NYSE: LLY) following the company's announcement that the DIAN-TU study did not meet the primary endpoint of showing an improvement for the drug over placebo. Divan believes some... More